

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- In a Phase II study of first-line zanidatamab and chemotherapy for HER2-positive advanced gastroesophageal adenocarcinomas, what was the approximate objective response rate?**
 - 30%
 - 45%
 - 62%
 - 84%
 - 100%
- The Phase III DESTINY-Gastric04 study evaluating trastuzumab deruxtecan versus ramucirumab/paclitaxel for previously treated HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma reported what finding at the interim analysis?**
 - Inferior overall survival (OS) outcomes with trastuzumab deruxtecan (T-DXd)
 - A nonsignificant trend toward OS improvement with T-DXd
 - A statistically significant improvement in OS with T-DXd
 - No efficacy findings have been reported yet
- Which of the following drug types best describes the mechanism of action of zanidatamab?**
 - Anti-PD-1/PD-L1 antibody
 - Biparatopic bispecific HER2-targeting antibody
 - CLDN18.2-targeting monoclonal antibody
 - TROP2-directed antibody-drug conjugate (ADC)
- Which of the following descriptions best reflects the design of the HERIZON-GEA-01 study of zanidatamab for metastatic HER2-positive gastroesophageal adenocarcinoma?**
 - A Phase I dose-escalation trial of zanidatamab and chemotherapy as first-line treatment
 - A Phase II dose-optimization trial of 2 different doses of zanidatamab monotherapy for relapsed/refractory disease
 - A Phase III trial comparing zanidatamab and chemotherapy with or without tislelizumab to trastuzumab and chemotherapy as first-line treatment
- What is the mechanism of action of the investigational agent AZD0901?**
 - Biparatopic HER2-targeting bispecific antibody
 - CLDN18.2-targeting ADC
 - HER2-targeting ADC
 - TROP2-targeting ADC
 - B7-H3 targeting ADC